Related references
Note: Only part of the references are listed.A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
Adam M. Spivak et al.
CLINICAL INFECTIOUS DISEASES (2014)
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)
Juan Berenguerl et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2014)
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
C. Korin Bullen et al.
NATURE MEDICINE (2014)
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Datsen George Wei et al.
PLOS PATHOGENS (2014)
Clinical applications of attenuated MVA poxvirus strain
Carmen Elena Gomez et al.
EXPERT REVIEW OF VACCINES (2013)
A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication
Felipe Garcia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation
Thomas Aagaard Rasmussen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control
Beatriz Mothe et al.
PLOS ONE (2012)
Therapeutic vaccines against HIV infection
Felipe Garcia et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection
Javier Garcia-Perez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial
Jonathan Z. Li et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection
Felipe Garcia et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Definition of the viral targets of protective HIV-1-specific T cell responses
Beatriz Mothe et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia
M. Medina-Ramirez et al.
JOURNAL OF VIROLOGY (2011)
Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation
Sifei Xing et al.
JOURNAL OF VIROLOGY (2011)
The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens
Carmen Elena Gomez et al.
JOURNAL OF VIROLOGY (2011)
High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control
Christoph T. Berger et al.
JOURNAL OF VIROLOGY (2011)
A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity
Sonsoles Sanchez-Palomino et al.
VACCINE (2011)
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pot and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
Felipe Garcia et al.
VACCINE (2011)
MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays
S. Kutscher et al.
GENE THERAPY (2010)
A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism
Nuria Gonzalez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
AIDS Clinical Trials Group 5197: A Placebo-Controlled Trial of Immunization of HIV-1-Infected Persons with a Replication-Deficient Adenovirus Type 5 Vaccine Expressing the HIV-1 Core Protein
Robert T. Schooley et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
Juan Garcia-Arriaza et al.
PLOS ONE (2010)
Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy
Thomas C. Greenough et al.
VACCINE (2008)
Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy
Lucy Dorrell et al.
VACCINE (2007)
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B
Carmen Elena Gomez et al.
VACCINE (2007)
CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load
Photini Kiepiela et al.
NATURE MEDICINE (2007)
Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses
Beatrice O. Ondondo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine
Lucy Dorrell et al.
JOURNAL OF VIROLOGY (2006)
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses
Florian Bihl et al.
JOURNAL OF IMMUNOLOGY (2006)
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control
R Zuñiga et al.
JOURNAL OF VIROLOGY (2006)
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals
Y Lévy et al.
AIDS (2006)
Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection
F García et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Biphasic decline of CD4 cell count during scheduled treatment interruptions
C Fagard et al.
AIDS (2005)
Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption
E Florence et al.
CLINICAL INFECTIOUS DISEASES (2004)
R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism
J Blanco et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection
A Oxenius et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
